US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

503.80

+2.920.58%

Number of Gainers:2

Number of Losers:2

Number of Flat:- -

PE:- -

High:521.94

Open:498.04

Low:489.68

Close:500.88

Loading ...

Tempus AI Initiated at Buy by BTIG

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Tempus AI Inc : Btig Initiates Coverage With Buy Rating; Target Price $60

THOMSON REUTERS

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

Simply Wall St.

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week

Simply Wall St.

BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

BRIEF-Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation

Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation

THOMSON REUTERS

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?

Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)

Recursion Pharmaceuticals call volume above normal and directionally bullish

Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing

THOMSON REUTERS

Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":503.8005,"timestamp":1745263226268,"preClose":500.88416,"halted":0,"volume":21868323,"delay":0,"changeRate":0.005822,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.916351,"latestTime":"04-21 15:20:26 EDT","open":498.04114,"high":521.93506,"low":489.6835,"amount":452453135.78857,"amplitude":0.064389,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.744561,"peRate":-7.355623,"turnoverRate":0.034323,"increases":2,"decrements":2,"flats":0,"marketCap":14186659712,"floatMarketCap":10579247360},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":521.93506,"amplitude":0.064389,"preClose":500.88416,"low":489.6835,"pbRate":"3.744561","latestPrice":503.8005,"volume":21868323,"delay":0,"open":498.04114,"prevYearClose":530.4984,"prevWeekClose":500.8842,"prevMonthClose":527.803,"prevQuarterClose":527.803,"fiveDayClose":514.1271,"twentyDayClose":609.3474,"sixtyDayClose":658.7855,"secType":"PLATE","market":"US","turnoverRate":0.034323,"peRate":-7.355623,"marketCap":14186659712,"floatMarketCap":10579247360,"timestamp":1745263226268,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":2,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529394503","title":"Tempus AI Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2529394503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529394503?lang=en_us&edition=fundamental","pubTime":"2025-04-22 02:21","pubTimestamp":1745259660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TEM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 14:21 ET (18:21 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1861558580.USD","BK4611","TEM","BK4613","LU1861559042.SGD"],"gpt_icon":0},{"id":"2529062800","title":"CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It","url":"https://stock-news.laohu8.com/highlight/detail?id=2529062800","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529062800?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:00","pubTimestamp":1745240409,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG  is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this company have returned -8.4%, compared to the Zacks S&P 500 composite's -5.6% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 12.9%. The key question now is: What could be the stock's future direction?Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.For the current fiscal year, the consensus earnings estimate of -$5.02 points to a change of -15.7% from the prior year. Over the last 30 days, this estimate has changed +2.1%.While earnings growth is arguably the most supe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-trending-130009505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","BK4556","AG","BK4585","BK4139","CRSP","BK4210","LU1861558580.USD","BK4611","BK4588"],"gpt_icon":0},{"id":"2529580659","title":"Tempus AI Inc : Btig Initiates Coverage With Buy Rating; Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2529580659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529580659?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:42","pubTimestamp":1745239328,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ1KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEM","LU1861559042.SGD","LU1861558580.USD","BK4611","BK4121","BK4613"],"gpt_icon":0},{"id":"2528090520","title":"Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2528090520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528090520?lang=en_us&edition=fundamental","pubTime":"2025-04-19 01:34","pubTimestamp":1744997654,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported significant advancements in its drug discovery initiatives and clinical studies, including dosing the first patient in a promising Phase 1 trial. Despite the broader market's flat performance over the past week, Recursion's stock price saw a 22% increase, suggesting that these developments reinforced investor confidence. The company's aim to accelerate drug discovery and clinical trials with enhanced data analytics may have added weight to this upward momentum.You should learn about the 4 possible red flags we've spotted with Recursion Pharmaceuticals .NasdaqGS:RXRX Earnings Per Share Growth as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-nasdaqgs-rxrx-taps-173414714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4609","BK4548","BK4139","BK4611","RXRX"],"gpt_icon":1},{"id":"2528777475","title":"CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2528777475","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528777475?lang=en_us&edition=fundamental","pubTime":"2025-04-18 06:00","pubTimestamp":1744927214,"startTime":"0","endTime":"0","summary":"In the latest market close, CRISPR Therapeutics AG  reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other hand, the Dow registered a loss of 1.33%, and the technology-centric Nasdaq decreased by 0.13%.Shares of the company witnessed a loss of 9.92% over the previous month, trailing the performance of the Medical sector with its loss of 8.46% and the S&P 500's loss of 6.3%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.26 per share, which would represent year-over-year growth of 11.89%. At the same time, our most recent consensus estimate is projecting a revenue of $5.24 million, reflecting a 947.2% rise from the equivalent quarter last year.Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to ref","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-220014129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRSP","BK4139","LU1861558580.USD","LU1861559042.SGD","BK4556","BK4585","BK4210","BK4588","BK4611","AG"],"gpt_icon":0},{"id":"2528979774","title":"Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2528979774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528979774?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:59","pubTimestamp":1744887565,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-buy-from-bank-of-america-securities-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-buy-from-bank-of-america-securities-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2129689605.HKD","BK4611","IE00B7SZLL34.SGD","LU1280957306.USD","LU2133065610.SGD","IE00BBT3K403.USD","LU2129689514.USD","CRSP","LU0256863811.USD","LU1880398471.USD","LU0868494617.USD","LU0106831901.USD","BK4504","LU1366192091.USD","LU1201861165.SGD","IE00BKVL7J92.USD","LU1880398554.USD","AG","LU0971096721.USD","LU0683600562.USD","LU1718418525.SGD","LU2129689431.USD","LU0149725797.USD","LU0320765489.SGD","LU1861558580.USD","BK4210","BK4553","BK4585","LU0053666078.USD","LU1894683348.USD","LU0310800965.SGD","LU0417517546.SGD","LU0208291251.USD","LU0648001328.SGD","LU1074936037.SGD","LU1883839398.USD","LU1668664300.SGD","BK4534","BK4588","LU0787776722.HKD","LU0306806265.USD","BAC","IE00B19Z3581.USD","LU1791807156.HKD","BK4207","LU0477156797.USD","IE00BFXG1179.USD","LU0070302665.USD","BK4556","LU0314106906.USD"],"gpt_icon":0},{"id":"2528843276","title":"CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2528843276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528843276?lang=en_us&edition=fundamental","pubTime":"2025-04-17 02:02","pubTimestamp":1744826552,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced investor sentiment, potentially reflecting strategic shifts within the company. This price movement stands out against a backdrop of broader market gains, as major indexes faced downward pressure due to trade tensions between the U.S. and China, particularly affecting the technology sector. However, the market overall rose by 8% in the last seven days, suggesting that CRISPR's movements might align with or have been amplified by these broader trends.We've identified 1 weakness for CRISPR Therapeutics that you should be aware of.NasdaqGM:CRSP Earnings Per Share Growth as at Apr 2025. Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-nasdaqgm-crsp-sees-180232066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","BK4556","LU1861559042.SGD","CRSP","LU1861558580.USD","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2527211273","title":"BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211273","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211273?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:42","pubTimestamp":1744807337,"startTime":"0","endTime":"0","summary":"BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World DataApril 16 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:HEALTHVERITY PARTNERS WITH RECURSION TO ENH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUAB5GPQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4611","BK4539","RXRX","BK4548","BK4609"],"gpt_icon":0},{"id":"2527241285","title":"HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241285","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241285?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:30","pubTimestamp":1744806600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data  technology and privacy-compliant data exchange, today announced that Recursion , a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/healthverity-partners-recursion-enhance-clinical-123000357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/healthverity-partners-recursion-enhance-clinical-123000357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4609","RXRX","BK4548","BK4139","BK4611","BK4539"],"gpt_icon":1},{"id":"2527482412","title":"BRIEF-Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527482412","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527482412?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:36","pubTimestamp":1744724185,"startTime":"0","endTime":"0","summary":"BRIEF-Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai InnovationApril 15 (Reuters) - Illumina Inc ILMN.O:ILLUMINA AND TEMPUS PARTNER TO DRIVE THE FUTURE OF PRE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA6XWGHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","LU1861559042.SGD","BK4535","ILMN","BK4613","BK4588","TEM","BK4121","BK4611","BK4534","LU1861558580.USD"],"gpt_icon":0},{"id":"2527411228","title":"Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527411228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527411228?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:15","pubTimestamp":1744722904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA6XWGHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","TEM","BK4613","BK4534","LU1861558580.USD","BK4588","BK4535","BK4121","ILMN","BK4548","BK4611","BK4585"],"gpt_icon":0},{"id":"2527414694","title":"Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527414694","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527414694?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:15","pubTimestamp":1744722900,"startTime":"0","endTime":"0","summary":"Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease. SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ --Illumina Inc.  and Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are:  challenges inherent in developing and launching new products and services, includi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/illumina-tempus-partner-drive-future-131500785.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illumina-tempus-partner-drive-future-131500785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4535","BK4121","ILMN","BK4585","BK4534","BK4588","LU1861558580.USD","LU1861559042.SGD","TEM","BK4611","BK4613"],"gpt_icon":1},{"id":"2527943012","title":"Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527943012","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527943012?lang=en_us&edition=fundamental","pubTime":"2025-04-15 13:07","pubTimestamp":1744693671,"startTime":"0","endTime":"0","summary":"Wall Street’s main indices kicked off the trading week in the green territory, albeit with minimal gains, as investors stayed on the sidelines while continuing to digest President Donald Trump’s temporary tax reprieve on technology companies.The S&P 500 recorded the highest gain, up 0.79 percent, while the Dow Jones came second at 0.78 percent. The tech-heavy Nasdaq was also up by 0.64 percent.Meanwhile, 10 companies, predominantly in the technology sector, bucked a broader market optimism, booking modest declines during the session. In this article, let us explore Monday’s 10 worst performers and the reasons behind their gains.A pharmacist in a hospital pharmacy stands next to a row of various drug containers.According to the FDA, the initiative was designed to replace animal testing with “more effective human-relevant methods” in the development of monoclonal antibody therapies and other drugs.According to the FDA, it will begin to encourage the inclusion of New Approach Methodologie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-recursion-pharmaceuticals-inc-rxrx-050751253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4609","RXRX","BK4539","BK4139","BK4611","BK4548"],"gpt_icon":1},{"id":"2527117371","title":"Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527117371","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527117371?lang=en_us&edition=fundamental","pubTime":"2025-04-15 08:05","pubTimestamp":1744675508,"startTime":"0","endTime":"0","summary":"20:03 EDT Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-460k-shares-of-recursion-pharmaceuticals-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-460k-shares-of-recursion-pharmaceuticals-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4611","BK4548","BK4585","BK4544","ARKK","BK4539","BK4139","BK4609","RXRX"],"gpt_icon":0},{"id":"2527140714","title":"Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527140714","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527140714?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:35","pubTimestamp":1744659310,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.  stands against other stocks that Jim Cramer discusses.In his latest appearance on CNBC’sSquawk on the Street, Jim Cramer suggested the recent tariffs might not simply be about economic leverage. He hinted at a deeper agenda within parts of the administration that goes beyond trade policy:. “There’s plenty of sense that something’s going to happen that’s going to take this away. In fact, just because of what we saw the other day with it going to 10 percent, I don’t see that at all. I think these are very different kinds of tariffs. I mean, this is a tariff where I think there’s some people with the administration who actually ultimately have a goal of regime change.“READ ALSO:Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key StocksandJim Cramer Questions Market Logic and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","TSYW.SI","BK4139","USAW.SI","NVIW.SI","BK4611",".IXIC","QLD","BK4609","BK4548","NQmain","SQQQ","USJW.SI","PSQ","QID","TQQQ","MNQmain","RXRX"],"gpt_icon":1},{"id":"2527199861","title":"Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527199861","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527199861?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:09","pubTimestamp":1744636140,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  shares soared 27.7% in the last trading session to close at $5.76. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.1% loss over the past four weeks.Earlier this month, the company announced that it has dosed the first patient in its early-stage study of investigational candidate, REC-3565, for treating relapsed or refractory (R/R) B-cell lymphomas. REC-3565 is a selective MALT1 inhibitor developed using Recursion Pharmaceuticals’ proprietary AI-driven Recursion OS platform. The growing optimism related to this development might have driven the recent share price rally.For Recursion Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RXRX going forward to see if this recent jump can","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4611","BK4007","BK4539","RXRX","BK4548","BK4609","AQST"],"gpt_icon":1},{"id":"2527995994","title":"Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527995994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527995994?lang=en_us&edition=fundamental","pubTime":"2025-04-13 22:50","pubTimestamp":1744555838,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-bruker-brkr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-bruker-brkr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4611","BK4609","BK4548","RXRX","LU1815336091.USD","BK4539","BK4139","LU0757428866.USD","BK4121","HCSG","BRKR"],"gpt_icon":0},{"id":"2526902066","title":"Recursion Pharmaceuticals call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2526902066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526902066?lang=en_us&edition=fundamental","pubTime":"2025-04-12 00:05","pubTimestamp":1744387514,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 9,589 calls trading, 1.6x expected, and implied vol increasing over 27 points...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-22?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-22?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4539","BK4609","BK4611","BK4139","RXRX"],"gpt_icon":0},{"id":"2526698309","title":"Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698309?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:32","pubTimestamp":1744378357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","BK4139","SDGR","BK4588","ABSI","BK4609","BK4121","RXRX","BK4548","BK4611","BK4539","CERT","BK4585"],"gpt_icon":0},{"id":"2526318698","title":"Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526318698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526318698?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:32","pubTimestamp":1744378357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4609","BK4588","ABSI","RXRX","BK4167","BK4611","CERT","SDGR","BK4139","BK4585","BK4539","BK4121"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}